Marketplace
For Industry Partners
For Innovators
Contact sales
Sign in
Join now
JA
Jennifer Altomonte
CEO/CSO
Fusix Biotech
Publications
20
Funding
3
Patents
2
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Nature 423 (6939), 550-555, 2003
Improved Insulin Sensitivity Is Associated With Restricted Intake of Dietary Glycoxidation Products in the db/db Mouse
Diabetes 51 (7), 2082-2089, 2002
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
The Journal of clinical investigation 114 (10), 1493-1503, 2004
Elevated vascular endothelial growth factor production in islets improves islet graft vascularization
Diabetes 53 (4), 963-970, 2004
Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice
American Journal of Physiology-Endocrinology and Metabolism 285 (4), E718-E728, 2003
Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism
Endocrinology 147 (12), 5641-5652, 2006
PPARα mediates the hypolipidemic action of fibrates by antagonizing FoxO1
American Journal of Physiology-Endocrinology and Metabolism 292 (2), E421-E434, 2007
Surgeon Yurii Voronoy (1895–1961)–a pioneer in the history of clinical transplantation: in Memoriam at the 75th Anniversary of the First Human Kidney Transplantation.
Transplant International 22 (12), 2009
Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma
Molecular Therapy 18 (2), 275-284, 2010
Fat depot-specific expression of adiponectin is impaired in Zucker fatty rats
Metabolism 52 (8), 958-963, 2003
Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance
Diabetes 54 (2), 367-372, 2005
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo
Molecular Therapy 16 (1), 146-153, 2008
rVSV (MΔ51)-M3 is an effective and safe oncolytic virus for cancer therapy
Human gene therapy 19 (6), 635-647, 2008
Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells
Cancer gene therapy 16 (3), 266-278, 2009
Oncolytic vesicular stomatitis virus as a viro-immunotherapy: defeating cancer with a “hammer” and “anvil”
Biomedicines 5 (1), 8, 2017
Inhibition of the IFN-β response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3
Molecular Therapy 16 (11), 1789-1797, 2008
Effects of glucose metabolism on the regulation of genes of fatty acid synthesis and triglyceride secretion in the livers⃞
Journal of lipid research 48 (7), 1499-1510, 2007
A novel chimeric oncolytic virus vector for improved safety and efficacy as a platform for the treatment of hepatocellular carcinoma
Journal of virology 92 (23), 10.1128/jvi. 01386-18, 2018
Characterization of magnetic viral complexes for targeted delivery in oncology
Theranostics 5 (7), 667, 2015
Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats
Hepatology 48 (6), 1864-1873, 2008
JA
Jennifer Altomonte
CEO/CSO
Fusix Biotech
Work experience
Fusix Biotech
CEO/CSO
Top industry applications
Not enough data yet.
Results may appear later and can be imperfect.
Open to opportunities in
Biopharmaceutics
Biotechnology
Cell Biology
Drug Delivery
Gene Therapy
Immunology
Last updated Aug 2024
Report Error
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
Subscribe
Company
About
Blog
Careers
Halo Awards
Support
FAQs
Help center
Feature requests
Contact support
Sponsors
Customer stories
Privacy Policy
Terms of Service
© 2026 Halo Cures, Inc.